News & Updates
Filter by Specialty:

SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
21 Apr 2022
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
20 Apr 2022
US-guided corticosteroid injection relieves symptoms in hip OA
An ultrasound (US)-guided intra-articular hip injection of corticosteroid and local anaesthetic, administered with advice and education, results in a rapid and sustained symptom response for individuals with hip osteoarthritis (OA), a study has shown.
US-guided corticosteroid injection relieves symptoms in hip OA
20 Apr 2022
AF affects one-third of patients after cryptogenic stroke, TIA
Almost 30 percent of patients who experience a cryptogenic stroke or transient ischaemic attack (TIA) go on to develop atrial fibrillation (AF), most of them asymptomatic, according to results of the NOR-FIB* study presented at EHRA 2022.
AF affects one-third of patients after cryptogenic stroke, TIA
19 Apr 2022
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.